Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

RemeGen Co. Ltd. Class H (9995) Stock Price & Analysis

6 Followers

9995 Stock Chart & Stats

HK$70.90HK$0.50(1.00%)
At close: 4:00 PM GMT+8
HK$70HK$80Aug 17Aug 31Sep 14Sep 28Oct 12Oct 26Nov 9
Day’s Range
HKD 69.95 - HKD 72.75
52-Week Range
HKD 60.00 - HKD 123.10
Previous Close
HKD 70.20
Volume
N/A
Average Volume (3M)
1.81M
Market Cap
HKD 56.21B
Enterprise Value
HKD 37.50B
Total Cash (Recent Filing)
HKD 5.51B
Total Debt (Recent Filing)
HKD 292.23M
Price to Earnings (P/E)
8.6
Beta
0.97
Next Earnings
Mar 31, 2027 (Est.)
EPS Estimate
0.99
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Strong Revenue And Profitability Inflection

The sharp TTM revenue increase and exceptionally high profitability demonstrate substantial current commercial traction for the company’s therapies. If these results persist, stronger earnings can support reinvestment in clinical development, commercialization, and the broader proprietary product pipeline over coming quarters.

Strong Cash Conversion

Operating and free cash flow closely tracking net income indicates that reported TTM earnings are converting into liquidity rather than remaining primarily accounting gains. This improves the company’s ability to fund operations and development internally, reducing dependence on external capital.

Much Lower Financial Leverage

The substantially lower debt-to-equity ratio gives RemeGen greater financial flexibility and reduces the burden of debt service compared with prior years. A stronger capital structure can help the company sustain research, commercialization, and other investment while absorbing operating volatility.

Bears Say

Earnings Durability Remains Uncertain

The abrupt shift from losses and cash burn to exceptionally high profitability makes the current earnings base difficult to underwrite as a stable trend. Results may remain lumpy if they depend on product mix, milestones, or other factors that do not repeat consistently.

Historically Inconsistent Cash Generation

Although current cash generation is strong, the prior record shows that RemeGen has not yet demonstrated consistent cash production through a full operating cycle. Repeated historical outflows indicate that future funding needs could rise again if profitability or product economics weaken.

Free Cash Flow Growth Is Negative

Negative TTM free cash flow growth tempers the significance of the current cash-flow level and suggests that liquidity generation is not accelerating. Without renewed growth, the company may have less internally generated capacity to expand commercialization or advance its development programs.

RemeGen Co. Ltd. Class H News

9995 FAQ

What was RemeGen Co. Ltd. Class H’s price range in the past 12 months?
RemeGen Co. Ltd. Class H lowest stock price was HK$60.00 and its highest was HK$123.10 in the past 12 months.
What is RemeGen Co. Ltd. Class H’s market cap?
RemeGen Co. Ltd. Class H’s market cap is HK$56.21B.
When is RemeGen Co. Ltd. Class H’s upcoming earnings report date?
RemeGen Co. Ltd. Class H’s next earnings report is estimated for Mar 31, 2027 (not yet confirmed), which is in 140 days.
How were RemeGen Co. Ltd. Class H’s earnings last quarter?
RemeGen Co. Ltd. Class H released its earnings results on Oct 29, 2026. The company reported HK$1.275 earnings per share for the quarter.
Is RemeGen Co. Ltd. Class H overvalued?
According to Wall Street analysts RemeGen Co. Ltd. Class H’s price is currently Undervalued.
Does RemeGen Co. Ltd. Class H pay dividends?
RemeGen Co. Ltd. Class H does not currently pay dividends.
What is RemeGen Co. Ltd. Class H’s EPS estimate?
RemeGen Co. Ltd. Class H’s EPS estimate is 0.99.
How many shares outstanding does RemeGen Co. Ltd. Class H have?
RemeGen Co. Ltd. Class H has 208,581,240 shares outstanding.
What happened to RemeGen Co. Ltd. Class H’s price movement after its last earnings report?
RemeGen Co. Ltd. Class H reported an EPS of HK$1.275 in its last earnings report. Following the earnings report the stock price went down -1.554%.
Which hedge fund is a major shareholder of RemeGen Co. Ltd. Class H?
Currently, no hedge funds are holding shares in HK:9995
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology